Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes:short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

Sculpher, Mark J, Lozano-Ortega, Greta, Sambrook, Jennifer, Palmer, Stephen, Ormanidhi, Orges, Bakhai, Ameet, Flather, Marcus, Steg, P Gabriel, Mehta, Shamir R and Weintraub, William (2009) Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes:short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. American Heart Journal, 157 (5). pp. 845-852. ISSN 0002-8703

Full text not available from this repository. (Request a copy)

Abstract

The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States.

Item Type: Article
Uncontrolled Keywords: acute coronary syndrome,anticoagulants,cost-benefit analysis,electrocardiography,enoxaparin,factor x,follow-up studies,guideline adherence,health care costs,humans,polysaccharides,practice guidelines as topic,time factors,united states
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:14
Last Modified: 21 Apr 2020 22:34
URI: https://ueaeprints.uea.ac.uk/id/eprint/46262
DOI: 10.1016/j.ahj.2009.02.017

Actions (login required)

View Item View Item